Reverse Network Pharmacology-Based Identification of 20-Hydroxyecdysone and Its Inhibition of Glioblastoma Malignant Phenotypes Through the PI3K/AKT Pathway.
- DOI
- 10.31083/fbl52978
- Published
- 2026 Aug 18
- Container
- Frontiers in bioscience (Landmark edition)
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.31083/fbl52978,
title = {Reverse Network Pharmacology-Based Identification of 20-Hydroxyecdysone and Its Inhibition of Glioblastoma Malignant Phenotypes Through the PI3K/AKT Pathway.},
author = {Zhang J and Wei C and Wang D and He R and Xiao X and Xu J and Lu J},
year = {2026},
journal = {Frontiers in bioscience (Landmark edition)},
doi = {10.31083/fbl52978},
url = {https://doi.org/10.31083/fbl52978}
}RIS
TY - JOUR TI - Reverse Network Pharmacology-Based Identification of 20-Hydroxyecdysone and Its Inhibition of Glioblastoma Malignant Phenotypes Through the PI3K/AKT Pathway. AU - Zhang J AU - Wei C AU - Wang D AU - He R AU - Xiao X AU - Xu J AU - Lu J PY - 2026 JO - Frontiers in bioscience (Landmark edition) DO - 10.31083/fbl52978 UR - https://doi.org/10.31083/fbl52978 ER -
APA
J, Z., C, W., D, W., R, H., X, X., J, X., & J, L. (2026). Reverse Network Pharmacology-Based Identification of 20-Hydroxyecdysone and Its Inhibition of Glioblastoma Malignant Phenotypes Through the PI3K/AKT Pathway.. Frontiers in bioscience (Landmark edition). https://doi.org/10.31083/fbl52978
Source records
- pubmed · retrieved 2026-09-26T01:10:41.149Z
- europe-pmc · retrieved 2026-09-26T01:10:41.169Z